Global Iodinated Contrast Media in Interventional X-Ray Market, By Route of Administration (Intravenous, Oral, Rectal, Others), Indication (Cardiology, Neurology, General Surgery, Oncology, Urology), Agent Type (Non-Ionic, Ionic), End User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End Users), Distribution Channel (Direct Tender, Retail Sales and Other) – Industry Trends and Forecast to 2031.
Iodinated Contrast Media in Interventional X-Ray Market Analysis and Size
The iodinated contrast media in interventional X-ray market, specifically iodinated contrast media, is projected for substantial growth with 3.9 million global deaths annually due to cardiovascular disease, the expiration of patents held by various companies will pave the way for generic producers, reducing technology costs. This shift is anticipated to broaden access to the technology's benefits, addressing a pressing healthcare concern.
Data Bridge Market Research analyses the global iodinated contrast media in interventional X-Ray market, which was USD 2.64 billion in 2023, is expected to reach USD 4.15 billion by 2031, at a CAGR of 5.80% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Route of Administration (Intravenous, Oral, Rectal, Others), Indication (Cardiology, Neurology, General Surgery, Oncology, Urology), Agent Type (Non-Ionic, Ionic), End User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End Users), Distribution Channel (Direct Tender, Retail Sales and Other)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bayer AG (Germany), Iso-Tex Diagnostics, Inc. (U.S.), Bracco Diagnostic Inc. (Italy), Novalek Pharmaceuticals Pvt. Ltd. (India), TAEJOON PHARM (South Korea), Unijules Life Sciences Ltd (India), General Electric (U.S.), Guerbet (France), J.B.Pharma (India)
|
|
Market Opportunities
|
|
Market Definition
Iodinated contrast media in interventional X-ray refers to a type of contrast agent containing iodine that enhances visibility of blood vessels and soft tissues during medical imaging procedures. Widely used in interventional radiology, it helps improve the clarity of X-ray images, aiding in the diagnosis and treatment of cardiovascular conditions. The market for this technology is expected to grow significantly, driven by increasing demand and accessibility.
Global Iodinated Contrast Media in Interventional X-Ray Market Dynamics
Drivers
- Rising Cardiovascular Disease Cases Increasing Demand for Advanced Diagnostic Tools
The escalating prevalence of cardiovascular diseases (CVD) globally, causing 3.9 million deaths annually, is a primary driver for the iodinated contrast media in interventional X-Ray market. As the incidence of cardiac conditions continues to surge, there is an increasing demand for advanced diagnostic tools, such as interventional X-Ray with iodinated contrast media, to facilitate accurate and timely diagnosis, leading to a substantial market growth.
- Patent Expirations and Generic Competition
The upcoming expiration of patents held by various companies is a significant driver shaping the iodinated contrast media market. As these patents expire, it opens avenues for generic pharmaceutical producers to enter the market. This influx of generic alternatives is expected to intensify competition, reducing the overall cost of the technology. Lower prices are such asly to enhance accessibility, enabling a broader population to avail the advantages of interventional X-Ray procedures, further driving the market expansion.
Opportunities
- Technological Advancements and Diversification Reducing the Risk of Adverse Reactions
Ongoing technological advancements in iodinated contrast media offer opportunities for enhanced formulations with improved safety profiles and diagnostic capabilities. Continuous research and development can lead to innovations such as low-osmolar contrast agents, reducing the risk of adverse reactions. Additionally, diversifying the applications of contrast media beyond cardiovascular interventions to other medical fields, such as oncology or neurology, can open up new markets and revenue streams, further contributing to the growth of the interventional X-Ray market.
- Emerging Markets and Global Healthcare Accessibility
The expanding healthcare infrastructure in emerging markets, coupled with a growing awareness of diagnostic procedures, presents a considerable opportunity for iodinated contrast media. As healthcare systems in developing regions improve, the demand for advanced imaging technologies is such asly to rise. Moreover, initiatives to enhance global healthcare accessibility may lead to increased adoption of interventional X-Ray procedures using iodinated contrast media, creating a broader market and contributing to the technology's global expansion.
Restraints/Challenges
- Renal Toxicity Concerns Restricting the Usage of Iodinated Contrast Media
Iodinated contrast media can pose a risk of renal toxicity, particularly in patients with pre-existing kidney conditions. The use of these agents may lead to contrast-induced nephropathy, limiting their application in individuals with compromised renal function. This concern has prompted careful consideration and monitoring, restricting the usage of iodinated contrast media in certain patient populations.
- Allergic Reactions and Adverse Effects
The potential for allergic reactions and adverse effects associated with iodinated contrast media. Some patients may experience mild to severe allergic responses, ranging from skin rashes to life-threatening anaphylaxis. This restricts the use of these agents in individuals with a history of iodine-related allergies.
This global iodinated contrast media in interventional X-Ray market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global iodinated contrast media in interventional X-Ray market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2021, GE Healthcare bolstered its ultrasound portfolio and advanced into surgical imaging by acquiring BK Medical. This strategic move not only expanded GE's capabilities but also contributed to the development of precision health through the integration of BK Medical's expertise
- In 2021, Koninklijke Philips N.V. collaborated with DiA Imaging Analysis Ltd. to enhance operational efficiency and care accessibility for point-of-care (POC) clients both within and outside hospitals. Philips leveraged DiA's automated solutions, integrated with ultrasound devices, aiming to improve diagnostic capabilities
- In 2019, General Electric strengthened its position in the Japanese market by transferring marketing rights for four diagnostic imaging agents through an agreement with Daiichi Sankyo Company. This move, completed in 2019, facilitated GE Healthcare's expansion and enhancement of diagnostic imaging agents in Japan, contributing to increased business presence
Global Iodinated Contrast Media in Interventional X-Ray Market Scope
The global iodinated contrast media in interventional X-Ray market is segmented on the basis of route of administration, indication, agent type, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Route of Administration
- Intravenous
- Oral
- Rectal
- Others
Indication
- Cardiology
- Neurology
- General Surgery
- Oncology
- Urology
Agent Type
- Non-Ionic
- Ionic
End-User
- Hospital/Clinical Laboratories
- Physician Offices
- Reference Laboratories
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Other
Global Iodinated Contrast Media in Interventional X-Ray Market Regional Analysis/Insights
The global iodinated contrast media in interventional X-Ray market is analyzed and market size insights and trends are provided by route of administration, indication, agent type, end-user and distribution channel as referenced above.
The major countries covered in the global iodinated contrast media in interventional X-Ray market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the iodinated contrast media market, driven by widespread adoption in CT procedures and the availability of non-ionic stable iodinated agents, enhancing diagnostic precision. Government initiatives promoting cancer and cardiac awareness, coupled with the introduction of innovative contrast agent products by various companies, contribute to the region's projected growth at an accelerated rate.
The Asia-Pacific is experiencing the significant growth in the market share in interventional X-Ray, driven by widespread adoption of advanced imaging techniques and the growing accessibility of non-ionic stable iodinated agents, enhancing diagnostic capabilities. Furthermore, the escalating healthcare expenditure and the proliferation of hospitals and imaging centers in China and India are major contributors, amplifying the demand for iodinated contrast media in interventional X-ray procedures.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global iodinated contrast media in interventional X-Ray market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global iodinated contrast media in interventional X-Ray market., impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global iodinated contrast media in interventional X-Ray market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Iodinated Contrast Media in Interventional X-Ray Market Share Analysis
The global iodinated contrast media in interventional X-Ray market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global iodinated contrast media in interventional X-Ray market.
Key players operating in the global iodinated contrast media in interventional X-Ray market include:
- Bayer AG (Germany)
- Iso-Tex Diagnostics, Inc. (U.S.)
- Bracco Diagnostic Inc. (Italy)
- Novalek Pharmaceuticals Pvt. Ltd. (India)
- TAEJOON PHARM (South Korea)
- Unijules Life Sciences Ltd (India)
- General Electric (U.S.)
- Guerbet (France)
- J.B.Pharma (India)
SKU-